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OBJECTIVE — In this study, we used neurocognitive assessment and neuroimaging to ex-
amine brain function in youth with type 1 diabetes studied prospectively from diagnosis.
RESEARCH DESIGN AND METHODS — We studied type 1 diabetic (n  106) and
control subjects (n  75) with no signiﬁcant group difference on IQ at baseline 12 years
previously by using the Wechsler Abbreviated Scale of General Intelligence, magnetic resonance
spectroscopy and imaging, and metabolic control data from diagnosis.
RESULTS — Type1diabeticsubjectshadlowerverbalandfullscaleIQsthancontrolsubjects
(both P  0.05). Type 1 diabetic subjects had lower N-acetylaspartate in frontal lobes and basal
ganglia and higher myoinositol and choline in frontal and temporal lobes and basal ganglia than
control subjects (all P  0.05). Type 1 diabetic subjects, relative to control subjects, had
decreased gray matter in bilateral thalami and right parahippocampal gyrus and insular cortex.
White matter was decreased in bilateral parahippocampi, left temporal lobe, and middle frontal
area (all P  0.0005 uncorrected). T2 in type 1 diabetic subjects was increased in left superior
temporalgyrusanddecreasedinbilaterallentiformnuclei,caudatenucleiandthalami,andright
insular area (all P  0.0005 uncorrected). Early-onset disease predicted lower performance IQ,
and hypoglycemia was associated with lower verbal IQ and volume reduction in thalamus; poor
metabolic control predicted elevated myoinositol and decreased T2 in thalamus; and older age
predicted volume loss and T2 change in basal ganglia.
CONCLUSIONS — This study documents brain effects 12 years after diagnosis in a type 1
diabeticsamplewhoseIQatdiagnosismatchedthatofcontrolsubjects.Findingssuggestseveral
neuropathological processes including gliosis, demyelination, and altered osmolarity.
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T
hecentralnervoussystem(CNS)isa
major organ system affected in type
1 diabetes, as both cerebral glucose
andinsulinlevelsarefrequentlyabnormal
even when diabetes is well controlled (1).
Intracellular calcium toxicity and excito-
toxic cellular damage, triggered by the
synaptic release of excessive glutamate,
have been identiﬁed as two potentially
important mechanisms that produce se-
lective neuronal necrosis during severe
hypoglycemia (1), but other metabolite
changes may also be important. Hyper-
glycemia disrupts blood-brain barrier
function and depresses cerebral blood
ﬂow acutely, whereas chronic hypergly-
cemia is associated with cerebrovascular
disease and neuropathy (1). The impact
ontheCNSofosmoticchangesassociated
with constantly ﬂuctuating glucose levels
is unclear. Neurotransmitter pathways
mayalsobeaffectedindiabetes,asinsulin
isinvolvedinregulationoftheamineneu-
rotransmitters (1).
There is a growing body of literature
documenting pathophysiological CNS
changes and neurocognitive deﬁcits in
adults with type 1 diabetes (2–6) as some-
times, but not universally, linked to spe-
ciﬁc illness variables such as disease du-
ration or history of severe hypoglycemia
or chronic hyperglycemia. Cognitive dif-
ﬁculties have also been reported in chil-
dren, with deﬁcits most evident in those
with early-onset (5 years old) disease
(7,8). Neuroimaging studies of youth
have been limited to date (9,10) and un-
derstandingoftheimpactoftype1diabe-
tes on neurodevelopment is still based
largely on inferences drawn from neuro-
cognitive studies and from adult neuro-
imaging reports. Controlled, longitudinal
studies are particularly informative in
documenting illness-related changes in
the CNS. The Diabetes Control and Com-
plications Trial (DCCT) (11) showed no
deterioration in cognitive function in ei-
ther conventionally or intensively treated
patients over an 18-year period. How-
ever,thisstudydidnotenrollparticipants
at diagnosis and recruitment was limited
to those 13 years of age. Thus, the
DCCT was unable to document any
illness-related effects that may have oc-
curred before recruitment—in particular,
the impact of diabetes on a developing
CNS. Children have high cerebral energy
needs associated with brain growth and
“neural pruning” and may be more sensi-
tive than adults to glucose ﬂuctuations
(1,7).Itisimportanttodocumentthespe-
ciﬁc neuropathological correlates of type
1diabetesinyoungerpopulations,asbet-
ter understanding of the impact of
childhood-onsetdiseaseonCNSdevelop-
ment will facilitate evidence-based pedi-
atric management regimens.
Previously,weidentiﬁedneurocogni-
tive deﬁcits 6 years after disease onset in
youth studied prospectively from diagno-
sis (12). The current study reevaluated
this cohort 12 years after study inception.
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METHODS— Consecutive patients
admittedtotheRoyalChildren’sHospital,
Melbourne, with newly diagnosed type 1
diabetes between 1990 and 1992 (n 
133) together with healthy control sub-
jects (n  126), stratiﬁed for age and sex.
AhistoryofCNSdiseaseortraumawasan
exclusion criterion. Twelve years later, all
participants who could be located (125
type 1 diabetic patients and 93 control
subjects: 94 and 74%, respectively) using
the study database, Royal Children’s Hos-
pital, Melbourne and adult diabetes clin-
ics, private endocrinologists, and the
Health Insurance Commission were in-
vited to take part in the current study. Of
those located, 106 type 1 diabetic and 75
control subjects agreed to participate
(rates of 85 and 81%, respectively).
Allparticipantsunderwentneurocog-
nitive testing. Participants were consecu-
tively invited to undergo neuroimaging
until available funding was exhausted.
Blood glucose levels (BGLs) of diabetic
participants were determined before as-
sessment by capillary sample to ensure
that subjects had a reading 4 mmol/l.
This study was approved by the Human
Ethics Research Committee of the Victo-
rian Government Department of Human
Services.
Measures
Neurocognitive assessment. The Wechs-
ler Abbreviated Scale of General Intelli-
gence (13) is a standardized, brief mea-
sure of intelligence providing full scale
(FSIQ), verbal (VIQ), and performance
(PIQ) IQ scores (mean  SD 100  15).
Magnetic resonance spectroscopy and
imaging. Imaging was carried out on a
3-T scanner (GE Healthcare, Milwaukee,
WI).
Magnetic resonance spectroscopy. Bi-
lateral single-voxel spectra were acquired
using a standard PRESS sequence to pro-
vide a metabolite proﬁle from three brain
regions of interest (ROIs): basal ganglia
and frontal and temporal lobes. The ROIs
were positioned using T1-weighted scout
images. Basal ganglia ROIs were posi-
tionedoverthelentiformnuclei,temporal
lobeROIswerepositionedtoincludehip-
pocampus and mesial temporal struc-
tures, and frontal lobe ROIs were placed
above the third ventricle sufﬁciently pos-
terior to avoid interference from curva-
ture of the skull. Acquisition parameters
were TE/TR  30/3000 ms. For frontal
andtemporalspectra,isotropic2-cmvox-
els were used, and for basal ganglia voxel
size was 2  2  1.5 cm. Data were ana-
lyzedusingsoftwarepackages,SAGE/IDL
(GE Healthcare; WI/RSI, Boulder, CO)
and LCModel (14), with a basis set of 15
metabolites acquired on the same spec-
trometer. Data were included in analyses
if the Cramer-Rao lower bound was
30% as determined by LCModel. Re-
sults are presented in institutional units
approximating millimoles per liter. In
vivoprotonmagneticresonancespectros-
copy (MRS) of brain provides information
on the tissue content of total N-acetylaspar-
tate (NAA) (including N-acetylaspartylglu-
tamate), creatine  creatine phosphate,
myoinositol, trimethylamines or choline-
containing metabolites (Cho), and glu-
tamine  glutamate.
Magneticresonanceimaging:volumetry.
A fast spoiled gradient-recalled echo at
steady-state sequence was used (TR/TE/
TI  13.8/2.7/500 ms, voxel size 0.48 
0.48  2 mm). For T2 relaxometry, a
modiﬁed, optimized Carr-Purcell-
Meiboom-Gill multiecho sequence (14)
was used (eight echoes, TE  28.9–231
ms, TR  6.24 s, 24 slices, 5-mm slice
thickness,in-planevoxelsize0.941.88
mm). The slice plane was perpendicular
to the long axis of the hippocampus. T2
mapsweregeneratedbyﬁttingtoamono-
exponential model with the inclusion of a
baseline that minimizes the contribution
of long T2 components (mainly cerebro-
spinal ﬂuid) to the ﬁt. For analyses, images
were warped to standard space in which
they could be compared and smoothed
(with a 10-mm kernel). All analyses were
performed using SPM2 (http://www.ﬁl.ion.
ucl.ac.uk/spm/software/spm2). Separate gray
matterand whitemattervolumetryanalyses
were performed using optimized voxel-
based morphometry (VBM) (15). Voxel-
wise T2 changes were assessed using the
approach of voxel-based relaxometry (16).
Biomedical measures. Participants with
diabetes diagnosed at age 5 years were
classiﬁed as having early-onset disease.
Participants reported any episodes from
diagnosis of hypoglycemia associated
with seizure/coma, and these were cor-
roborated through scrutiny of medical
records. The sample was dichotomized
into those who reported no events and
those with a history of 1 event. A1C
measurements from diagnosis were ob-
tained for each patient (range 9–57, me-
dian 37) from hospital and clinic
databases. The percentage of total time
from diagnosis that A1C was 9.0% was
calculated to estimate overall metabolic
control.
Statistical analyses
SPSS (version 14; SPSS, Chicago, IL) was
used for statistical analyses of demo-
graphic, IQ, and MRS data.
IQ. Group differences were examined
using ANCOVA, covarying for socio-
economic status (SES), FSIQbaseline, and
time between baseline and current
assessment.
MRS. Mean bilateral metabolite concen-
trations in each ROI were used in analy-
ses. Group differences were examined
using ANCOVA with age as a covariate.
Magnetic resonance imaging. ANCOVA
was used to examine group differences in
volume and T2, covarying for age. Vol-
ume analyses also included total brain
volume and sex as covariates.
Multiplelinearregressionwasusedto
predict IQ from illness variables (age of
disease onset, hypoglycemia, and meta-
bolic control), SES, FSIQbaseline, and time
betweenbaselineandcurrentassessment.
Ageofdiseaseonsetwashighlycorrelated
with age; hence, age was used as a predic-
tor for regression analyses of MRS/
magnetic resonance imaging (MRI) data,
together with hypoglycemia and meta-
bolic control. MRI regression analyses
wererestrictedtoanatomicalareasshown
to differ in the initial type 1 diabetic and
control comparisons.
RESULTS— Sample characteristics of
participants are presented in Table 1.
Type 1 diabetic and control participants
did not differ on FSIQbaseline, age, sex ra-
tio, SES, or psychiatric symptoms. Time
between baseline and current assessment
was shorter in type 1 diabetic subjects
(95% CI 0.37–1.0 years). Type 1 diabetic
and control participants who underwent
neuroimaging did not differ signiﬁcantly
on age or sex ratio, and there were no
differences between type 1 diabetic sub-
jects who had neuroimaging and those
who did not on age of disease onset, hy-
poglycemia, or metabolic control. Group
mean scores  SD on IQ and MRS and
MRI variables are presented in Tables 2
and 3.
Group (type 1 diabetic and control
participants) differences on IQ and
MRS/MRI variables
IQ. Type 1 diabetic subjects had lower
VIQ(P0.03)andFSIQ(P0.05)than
control subjects.
Type 1 diabetes and the developing brain
446 DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009MRS. The largest mean differences were in
myoinositol and NAA, with myoinositol
higher and NAA lower in type 1 diabetic par-
ticipants.Smallerstatisticallysigniﬁcantmean
differences (type 1 diabetic participants
higher) were found in Cho in all locations.
MRI. Type1diabeticsubjects,relativeto
control subjects, had decreased gray mat-
tervolumeinbilateralthalami,rightpara-
hippocampal gyrus, and right insular
cortex(supplementalFigureA1,available
in online appendix at http://dx.doi.org/
10.2337/dc08-57). Mean white matter
volume was decreased in bilateral mesial
temporal lobes (parahippocampal re-
gion), in other areas of the left temporal
lobe, and in the left-middle frontal area.
T2relaxationtimesintype1diabeticpar-
ticipants were increased in the left supe-
rior temporal gyrus and decreased in
bilateral lentiform nuclei, caudate nuclei
andthalami,andtherightinsulararea(all
P  0.0005 uncorrected).
Illness-related predictors of CNS
outcome in type 1 diabetic
participants
Regression analyses of illness-related pre-
dictors of IQ, MRS, and MRI ﬁndings are
presented in supplemental Table A1,
available in an online appendix.
IQ. Ineachregression,SESandFSIQbase-
linecontributedsigniﬁcantlytothemodel.
In addition, hypoglycemia predicted
lowerVIQ(R
2change0.032,P0.01)
and early disease onset predicted lower
PIQ (R
2 change  0.135, P  0.001) and
FSIQ (R
2 change  0.064, P  0.001).
The verbal IQ of the hypoglycemia sub-
group was nearly 1⁄3 SD below that for
type 1 diabetic patients with no hypogly-
cemia (adjusted mean  SEM 93.8  1.3
vs. 98.2  1.1). Early-onset participants
Table 2—Group (type 1 diabetic and control participants) differences on IQ and metabolites
Outcome variable
Means Mean difference*
P
Type 1
diabetes Control Estimate 95% CI
IQ
VIQ 96.2 100.4 3.64 6.97 to 0.30 0.03
PIQ 106.4 109.1 2.02 5.46 to 1.43 0.25
FSIQ 101.3 105.1 3.03 6.07 to 0.00 0.05
Metabolite
mI basal ganglia 3.46 3.17 0.29 0.11 to 0.48 0.002
mI frontal lobe 4.17 3.52 0.65 0.46 to 0.84 0.001
mI temporal lobe 4.39 3.91 0.48 0.22 to 0.75 0.001
Cr basal ganglia 6.88 6.96 0.08 0.32 to 0.16 0.5
Cr frontal lobe 5.39 5.37 0.01 0.12 to 0.15 0.9
Cr temporal lobe 5.31 5.32 0.02 0.29 to 0.26 0.9
Glx basal ganglia 11.50 11.37 0.14 0.35 to 0.63 0.6
Glx frontal lobe 9.99 9.76 0.16 0.26 to 0.58 0.4
Glx temporal lobe 8.43 8.31 0.12 0.37 to 0.61 0.6
Cho basal ganglia 1.63 1.56 0.07 0.01 to 0.14 0.027
Cho frontal lobe 1.61 1.48 0.13 0.07 to 0.19 0.001
Cho temporal lobe 1.72 1.64 0.09† 0.00 to 0.18† 0.04†
NAA basal ganglia 7.98 8.47 0.49 0.83 to 0.15 0.005
NAA frontal lobe 8.27 8.67 0.41 0.65 to 0.16 0.001
NAA temporal lobe 7.50 7.84 0.35 0.72 to 0.03 0.07
*Adjusted mean difference estimate (from ANCOVA model) is type 1 diabetes  control. †This analysis was
based on nonparametric procedures because of an extreme value in the original data set; the estimate and
approximate 95% CI are for a difference in the location of the populations. The P value is from the
Mann-Whitney U test. Cr, creatine  creatine phosphate; Glx, glutamine  glutamate; mI, myoinositol.
Table 1—Sample characteristics
Type 1
diabetes Control
Mean difference (type 1
diabetes  control)
P Estimate 95% CI
Sample size (n) 106 75
Age (years) 20.5  4.3 21.0  3.8 0.50 1.74 to 0.74 0.4
Female sex (%) 49 51 1.6 16.0 to 12.9 0.9
SES (1  high, 7  low) 4.3  1.1 4.1  1.1 0.25 0.08 to 0.59 0.14
Mental health (YSR/YASR total t score) 48.7  11.5 49.5  11.0 0.75 4.17 to 2.66 0.7
FSIQbaseline 108.0  15.1 110.6  12.2 2.66 6.83 to 1.52 0.2
Time between baseline assessment and12-year
follow-up (years)
12.7  1.1 12.0  1.1 0.70 0.37 to 1.03 0.001
Neuroimaging (n)7 9 5 1
Age (years) 20.3  4.3 20.6  3.6 0.25 1.69 to 1.18 0.7
Female sex 41 47 6.6 2.3 to 10.5 0.5
BGL at imaging (mmol/l) 12.6  5.4
BGL at neurocognitive testing (mmol/l) 11.7  5.9
Most recent A1C (%) 9.2  1.8
Age at type 1 diabetes onset (years) 7.1  3.7
Early disease onset (%) 38
1 episode severe hypoglycemia (%) 44
Mean time A1C 9.0% (%) 41.95  26.31
Data are means  SD unless otherwise noted. YASR, Young Adult Self Report; YSR, Youth Self Report.
Northam and Associates
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1⁄3 SD below that for those with later-
onset type 1 diabetes (101.6  2.5 vs.
109.2  1.7 and 97.8  2.1 vs. 103.4 
1.4, respectively).
MRS. Poor metabolic control predicted
higher levels of myoinositol in basal gan-
glia (R
2 change  0.055, P  0.04), and
older age predicted lower levels of glu-
tamine  glutamate in frontal lobes (R
2
change  0.116, P  0.01) and NAA in
temporal lobes (R
2 change  0.133, P 
0.01).
MRI. Regression analyses of MRI data in
areas implicated in the previous group
comparisons revealed the dominating in-
ﬂuence of age in explaining variation in
volume and T2: R
2 change  0.247, P 
0.001 (gray matter volume lentiform); R
2
change  0.060, P  0.02 (gray matter
volume thalamus); R
2 change  0.578,
P  0.001 (T2 lentiform); and R
2
change  0.418, P  0.001 (T2 thala-
mus). Hypoglycemia predicted reduced
gray matter volume in the thalamus (R
2
change  0.045, P  0.03), and poor
metaboliccontrolwasassociatedwithde-
creased T2 in the thalamus (R
2 change 
0.021, P  0.05).
In view of the strong association be-
tween older age and volume and T2 re-
duction in type 1 diabetic subjects, we
investigatedhowgroupandagepredicted
each of the MRI variables. The models in-
cluded an interaction term of group by
age, which was statistically signiﬁcant in
all analyses. For volume, the models pre-
dicted small positive changes with age for
control subjects and relatively larger neg-
ative changes for type 1 diabetic subjects
(lentiform,Pinteraction0.002,ageslopes:
type1diabeticsubjects0.0038,control
subjects 0.0001; thalamus, Pinteraction 
0.046,ageslopes:type1diabeticsubjects
0.0025, control subjects 0.0012). For
T2, the models predicted relatively larger
negative changes for type 1 diabetic sub-
jects than for control subjects (lentiform,
Pinteraction  0.013, age slopes: type 1 di-
abetic subjects 5.11, control subjects
3.17; thalamus, Pinteraction  0.017, age
slopes: type 1 diabetic subjects  5.25,
control subjects  2.85).
BGL at time of testing. Correlations be-
tween BGL before neuropsychological as-
sessment and IQ scores and between BGL
before scanning and metabolite proﬁles
were calculated and ranged from r 
0.001 to r  0.242 (all P 0.05). To
furtherexaminethepossibleconfounding
of intercurrent hyperglycemia on study
ﬁndings, data from type 1 diabetic partic-
ipants with BGLs 15 mmol/l at the time
Table 3—Group (type 1 diabetic and control) differences on grey matter volume, white matter volume, and T2 relaxation time
Outcome variable Cluster*
Means† Mean difference‡
t§
Type 1
diabetic Control Estimate 99.9% CI
GM volume decrease
Left thalamus 1,718 0.531 0.568 0.038 0.005 to 0.071 3.93
Right thalamus 1,623 0.525 0.563 0.038 0.005 to 0.071 3.93
Left frontal precentral/insular gyrus 373 0.532 0.575 0.051 0.003 to 0.098 3.55
Right superior frontal gyrus 287 0.431 0.478 0.049 0.003 to 0.095 3.58
Right frontal precentral gyrus 78 0.349 0.390 0.046 0.003 to 0.088 3.60
Right parietal postcentral gyrus 104 0.375 0.417 0.046 0.002 to 0.089 3.51
Right parahippocampal gyrus 79 0.513 0.554 0.046 0.001 to 0.091 3.45
WM volume decrease
Right parahippocampal WM 183 0.275 0.329 0.050 0.006 to 0.094 3.82
Left parahippocampal WM 290 0.231 0.275 0.042 0.002 to 0.082 3.55
Left-middle frontal WM 207 0.149 0.201 0.049 0.007 to 0.090 3.94
Left temporal WM 156 0.092 0.131 0.037 0.003 to 0.071 3.69
Left insular WM 158 0.182 0.230 0.043 0.004 to 0.082 3.69
Left-middle temporal WM 126 0.386 0.458 0.074 0.006 to 0.142 3.56
T2 decrease
Left lentiform nucleus 299 625.5 638.0 14.3 1.0 to 27.6 3.63
Right lentiform nucleus 1,058 645.4 662.9 19.1 3.1 to 35.1 4.01
Left caudate nucleus 1,843 614.0 627.7 15.4 2.2 to 28.6 3.92
Right caudate nucleus 2,901 644.7 659.3 16.2 2.2 to 30.3 3.88
Left thalamus 496 678.8 693.2 15.5 1.78 to 29.2 3.81
Right thalamus 753 653.7 669.8 17.6 2.6 to 32.63 3.95
Red nuclei (bilaterally) 225 664.1 676.4 13.7 1.0 to 26.4 3.63
Right frontal WM 251 706.1 727.7 22.8 1.4 to 44.18 3.59
Right insular/superior temporal gyrus 146 712.0 736.0 26.0 1.2 to 50.9 3.53
Corpus callosum 24 706.9 722.0 15.7 0.7 to 30.7 3.52
Right parietal WM 23 716.6 732.4 16.3 0.3 to 32.3 3.44
T2 increase
Left-middle temporal GM 37 793.8 762.1 30.0 59.6 to 0.5 3.43
Magnetic resonance regions are indicated as abnormal by voxel-based analysis (type 1 diabetic versus control participants using a one-tailed t test at P  0.0005,
noncorrected). *The cluster size is the number of voxels in a contiguous volume of suprathreshold voxels. †Mean values of voxel-based data are not adjusted for
covariates. T2 values are in milliseconds; volume changes are in liters. ‡The mean difference is adjusted for covariates. §Since signiﬁcance is the selection criteria for
these areas, the t statistic is reported. The bidirectional CIs are shown at 99.9% (equivalent threshold to the two one-tailed t tests at P  0.0005). GM, gray matter;
WM, white matter.
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data were reanalyzed. Group differences
on VIQ and FSIQ became trends only
(P  0.06 and P  0.07, respectively).
The signiﬁcance of the group difference
on basal ganglia NAA was also reduced
(P0.08)afterremovaloftype1diabetic
participants with BGL 15 (n  19) at
the time of scanning. All other group dif-
ferences and illness-related predictors of
IQ and metabolites were unchanged.
CONCLUSIONS — This study is the
ﬁrst to document CNS effects 12 years
after diagnosis in youth with type 1 dia-
betes whose neurocognitive proﬁle at dis-
ease onset was not different from that of
control subjects. Metabolites and IQ re-
sults were largely unchanged after re-
moval of data from type 1 diabetic
participants with high BGLs at the time of
assessment, suggesting that study ﬁnd-
ings reﬂect stable changes in CNS func-
tion. Group differences on IQ were
marginal and appear to reﬂect the selec-
tive impact of speciﬁc illness risk factors.
Lower VIQ was associated with a positive
history of hypoglycemia, whereas early-
onset disease predicted lower PIQ and
FSIQ. The association between early-
onset disease and lower IQ, particularly
PIQ, is a consistent ﬁnding (7,8). Hypo-
glycemia-related effects on VIQ have also
been reported previously in the pediatric
literature(8,12)butwerenotfoundinthe
DCCT (11), suggesting that the develop-
ing CNS may be especially vulnerable to
hypoglycemia. It is important to note that
illness-related effects on IQ, although sta-
tistically signiﬁcant, are small, and indi-
viduals with type 1 diabetes function well
within the average range. However, even
milddecrementsinabilitymayhavefunc-
tional signiﬁcance during childhood
when new knowledge is being acquired.
Of participants who had reached school-
leaving age at follow-up (type 1 diabetic
subjects, n  76; control subjects, n 
55), 17% fewer type 1 diabetic subjects
than control subjects (68 vs. 85%, P 
0.01) completed year 12, the pretertiary
year of education in Australia.
This study showed lower mean NAA
and higher mean myoinositol and Cho in
type 1 diabetic subjects than in control
subjects. The magnitudes of these differ-
ences were in the range of 10–15% and
are similar to those reported for diseases
such as dementia, epilepsy, and Parkin-
son’s disease (17,18). There are also sim-
ilarities between current ﬁndings and
previous reports in diabetes (4,5,10), al-
though direct comparison is difﬁcult be-
cause methodology has varied, with
different brain regions assessed and some
samples including both type 1 and type 2
diabetic participants. With one exception
(10), study populations have been older
than the current sample. NAA is a marker
of neuronal density or viability, with
lower levels indicative of neuronal death
and/or decreased neuronal metabolism
(17). Lower mean NAA is consistent with
animal models of diabetes suggesting that
chronic hyperglycemia reduces neuronal
number and impedes myelination (19).
Although we were not able to relate NAA
directly to metabolic control in the cur-
rent study, NAA levels correlated in-
verselywithlifetimeglycemicexposurein
another report (5).
Myoinositol is a marker of changes in
osmolarity, and increased levels are asso-
ciated with both gliosis and demyelina-
tion (17). In the current study, poorer
metabolic control was associated with
higher levels of myoinositol in basal gan-
glia which, together with other reports of
elevated myoinositol in patients recover-
ing from diabetic ketoacidosis (20), sug-
gests that higher levels may represent a
homeostatic response of the brain to pro-
longed hyperglycemia. Cho levels are in-
creased with demyelination and other
forms of cell membrane breakdown, in-
cludinggliosis(17).Indiabetes,increases
in both myoinositol and Cho are consis-
tent with glial proliferation due to tissue
hypoxia in the context of chronically ele-
vated blood glucose levels (21). As with a
previous report (10), metabolite proﬁles
werenotrelatedtohistoryofhypoglycemia.
Volumetric measurements can iden-
tify regionally speciﬁc macroscopic atro-
phy associated with neuronal degene-
ration. Musen et al. (2), using VBM, re-
ported reduced gray matter densities in
temporal brain regions and left thalamus.
Our ﬁnding of decreased mean gray mat-
terinthalamusissimilar,but,inaddition,
we found reduced mean gray matter vol-
ume ininsularcortexandfrontalprecentral
regionsandareductioninmeanwhitemat-
ter volume in mesial temporal areas. Previ-
ous reports have linked VBM changes to a
previoushistoryofeitherchronichypergly-
cemia (2,3,8) and/or severe hypoglycemia
(2,8). In the current study, hypoglycemia
was associated with volume reduction in
the thalamus, poor control predicted de-
creased T2 in the thalamus, and there
were strong associations between older
age and reduced volume and T2 in ante-
rior and temporal brain regions as well as
thalamus, caudate, and lentiform nuclei.
The volume group differences found
in this study reach levels of 10%, com-
parable to changes in temporal lobe epi-
lepsyinwhichvolumereductionis10–
15% (22). T2 group differences of 3% in
thecurrentstudyaresmallerthanthoseof
5–20% reported in other CNS diseases
(23) and may in part reﬂect an osmotic
inﬂuence of acutely elevated glucose on
tissue water distribution as well as or in-
stead of any longer-term impact of the ill-
ness. In the current study, older age was
the strongest predictor of volume and T2
decreaseintype1diabeticsubjects.Older
age is a surrogate for later disease onset in
thiscohort,asdurationofillnesswascon-
trolled;hence,theseﬁndingsarecounter-
intuitive, given the consistent association
between early disease onset and neuro-
cognitive deﬁcits reported previously
(7,8,11). It is now recognized, though,
that CNS maturation continues into the
third decade of life (24), and it is possible
that ﬁndings reﬂect an interaction be-
tween type 1 diabetes and the ﬁnal stages
of neurodevelopment, with the early-
onset subgroup yet to experience this dis-
ruption. The suggestion by Biessels et al.
(25) that diabetes is a model for “acceler-
ated [CNS] aging” provides an alternative
explanation for our ﬁndings. That is,
rather than reﬂecting disrupted neurode-
velopment, the greater volume loss in our
older and later-onset participants may
represent the earliest stages of cerebral
microvascular disease or some other neu-
rodegenerative process.
The current ﬁndings are suggestive of
a number of possible illness-related neu-
ropathological processes, including glio-
sis, demyelination, and changes in os-
molarity and neural cell type/viability.
Anterior and temporal brain regions have
particularly high glucose demands and
increasedsensitivitytoglucosedisruption
(1);thus,itnotsurprisingthatthesebrain
regions show reduced brain volumes, al-
tered T2 relaxation times, and metabolite
changes. Relationships between speciﬁc
illness variables and CNS effects are more
difﬁculttodisentangle.Therewerestrong
associations between age and IQ and
structural brain changes but in the oppo-
site direction. Early-onset diabetes (and
younger age) was associated with lower
PIQ and FSIQ, whereas older age pre-
dictedlowerlevelsofNAA,reducedbrain
volumes, and altered T2. Metabolite pro-
ﬁlesaremoresuggestiveofhyperglycemia
than of hypoglycemia-mediated neuro-
Northam and Associates
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possible that speciﬁc illness variables
exert different effects on the CNS, but
inconsistent associations may also re-
ﬂect difﬁculties in obtaining reliable and
comprehensive metabolic control histo-
ries, including documentation of diabetes
complications. Further studies, involving
large multicenter cohorts, meticulous
collection of metabolic control histories,
documentation of diabetes complica-
tions, and tight control over the glycemic
level of participants at the time of assess-
ment, are needed to fully understand the
pathogenesis of CNS changes in child-
hood-onset diabetes.
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